Remodulin
NYHA Functional Class III, refractory to conventional therapy, NYHA class IV + 2 more
Treatment
20 Active Studies for Remodulin
Treatment for
NYHA Functional Class III
What is Remodulin
Treprostinil
The Generic name of this drug
Treatment Summary
Treprostinil is a drug that mimics the effects of prostacyclin, a natural substance that helps regulate blood pressure. It is used to treat pulmonary hypertension, a condition characterized by abnormally high blood pressure in the arteries of the lungs.
Remodulin
is the brand name
Remodulin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Remodulin
Treprostinil
2002
47
Effectiveness
How Remodulin Affects Patients
Treprostinil relaxes the blood vessels in the lungs and body, and stops platelets from clumping together. In animals, this leads to a decrease in the amount of pressure in the heart and an increase in how much blood it pumps. Treprostinil can also cause a decrease in heart rate and contraction, although no major effects on heart rhythm have been found. Taking treprostinil increases the risk of bleeding, and can cause symptoms like low blood pressure. People with asthma, COPD, or bronchial hyperreactivity may experience bronchospasms when inhaling treprostinil.
How Remodulin works in the body
Treprostinil is a medication used to treat pulmonary arterial hypertension. It works by opening potassium channels on cells and increasing levels of a molecule called cAMP, which both stimulates vasodilation in the arteries and prevents platelet aggregation. It also has anti-inflammatory properties.
When to interrupt dosage
The prescribed dosage of Remodulin depends upon the established condition, including refractory to traditional therapy, Pulmonary Arterial Hypertension and NYHA class IV. The measure of dosage deviates, depending on the method of delivery (e.g. Solution or Inhalant) specified in the table below.
Condition
Dosage
Administration
refractory to conventional therapy
2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Oral, Tablet, extended release - Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit
Pulmonary Hypertension
2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Oral, Tablet, extended release - Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit
NYHA Functional Class III
2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Oral, Tablet, extended release - Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit
NYHA class IV
2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Oral, Tablet, extended release - Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit
Pulmonary Arterial Hypertension
2.0 mg/mL, , 5.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 2.5 mg, 1.0 mg, 5.0 mg, 1.74 mg/mL, 0.125 mg, 0.25 mg, 1.0 mg/mL, 2.5 mg/mL, 40.0 mg/mL, 0.048 mg, 0.064 mg, 0.016 mg, 0.032 mg
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Inhalant, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Tablet, extended release, Oral, Tablet, extended release - Oral, Inhalant - Oral, Injection, Injection - Intravenous; Subcutaneous, Subcutaneous, Injection, solution - Subcutaneous, Inhalant; Kit - Oral, Inhalant; Kit
Warnings
Remodulin Contraindications
Condition
Risk Level
Notes
Severe Hepatic Impairment
Do Not Combine
There are 20 known major drug interactions with Remodulin.
Common Remodulin Drug Interactions
Drug Name
Risk Level
Description
Amifostine
Major
Treprostinil may increase the hypotensive activities of Amifostine.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Treprostinil.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Treprostinil.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Treprostinil.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Treprostinil.
Remodulin Toxicity & Overdose Risk
Symptoms of a treprostinil overdose can include flushing, headache, nausea, vomiting, diarrhea, low blood pressure, and seizures. Two cases of serious hemodynamic issues have been reported, one of which involved a child who received an accidental dose of 7.5 mg. In animal studies, treprostinil did not increase cancer risk, affect fertility or mating performance, or cause mutagenic or clastogenic effects. Additionally, no significant increases in tumors were found in rats given up to 10 mg/kg/day of oral treprostinil diolamine.
Remodulin Novel Uses: Which Conditions Have a Clinical Trial Featuring Remodulin?
54 active clinical trials are currently investigating the potential of Remodulin to mitigate Pulmonary Arterial Hypertension, NYHA Functional Class III and Pulmonary Arterial Hypertension.
Condition
Clinical Trials
Trial Phases
NYHA class IV
0 Actively Recruiting
NYHA Functional Class III
0 Actively Recruiting
refractory to conventional therapy
0 Actively Recruiting
Pulmonary Hypertension
30 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Pulmonary Arterial Hypertension
3 Actively Recruiting
Phase 1, Not Applicable, Phase 4
Remodulin Reviews: What are patients saying about Remodulin?
5
Patient Review
2/17/2016
Remodulin for Pulmonary Arterial Hypertension
5
Patient Review
8/4/2009
Remodulin for Pulmonary Arterial Hypertension
4.3
Patient Review
4/30/2016
Remodulin for Pulmonary Arterial Hypertension
4
Patient Review
8/12/2009
Remodulin for Pulmonary Arterial Hypertension
3
Patient Review
6/13/2010
Remodulin for Pulmonary Arterial Hypertension
3
Patient Review
6/19/2010
Remodulin for Pulmonary Arterial Hypertension
2.7
Patient Review
8/18/2010
Remodulin for Pulmonary Arterial Hypertension
1.7
Patient Review
1/10/2013
Remodulin for Pulmonary Arterial Hypertension
1
Patient Review
1/7/2011
Remodulin for Pulmonary Arterial Hypertension
Patient Q&A Section about remodulin
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What type of medication is Remodulin?
"Remodulin is a medication used to treat pulmonary arterial hypertension, which is high blood pressure in the arteries of your lungs. Remodulin can reduce symptoms associated with exercise."
Answered by AI
What is the drug Remodulin used for?
"This helps to decrease the number of hospital visits and improve your ability to exercise.
This medication is used to treat pulmonary arterial hypertension, a type of high blood pressure in the lungs. Treprostinil helps to improve symptoms such as shortness of breath and tiredness. This helps to decrease the number of hospital visits and improve your ability to exercise."
Answered by AI
What happens if you stop Remodulin?
"If you stop taking treprostinil suddenly, or if you decrease your dose too quickly, you may experience symptoms of pulmonary hypertension such as pain when breathing, dizziness, weakness, and fatigue."
Answered by AI
Is Remodulin a continuous infusion?
"Remodulin may be diluted with either 5% Dextrose Injection or 0.9% Sodium Chloride Injection, USP to a total volume not to exceed 20 mL.
Remodulin is a medication that is indicated to be given as a continuous infusion through either a subcutaneous line or an intravenous line. Remodulin is typically given through a subcutaneous line, but can be given intravenously if the subcutaneous route is not tolerated because of severe site pain or reaction. Remodulin can be diluted with either 5% Dextrose Injection or 0.9% Sodium Chloride Injection, USP to a total volume not to exceed 20 mL."
Answered by AI